Galapagos (GLPG)
(Delayed Data from NSDQ)
$29.58 USD
+0.24 (0.82%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.62 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.58 USD
+0.24 (0.82%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.62 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Zacks News
Buy These 4 Low-Beta Stocks to Counter Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Virco Mfg (VIRC), Galapagos NV (GLPG), Axonics (AXNX) and Stride (LRN) are well-poised to gain.
FDA Updates Labels of Esperion's (ESPR) Cholesterol-Lowering Drugs
by Zacks Equity Research
The label to Esperion's (ESPR) marketed drugs Nexletol and Nexlizet have been updated to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations.
Best Momentum Stocks to Buy for December 13th
by Zacks Equity Research
GLPG, BBVA and TW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 13, 2023.
New Strong Buy Stocks for December 13th
by Zacks Equity Research
TZOO, GLPG, BBVA, TW and STNE have been added to the Zacks Rank #1 (Strong Buy) List on December 13, 2023.
Dynavax Technologies (DVAX) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Dynavax Technologies (DVAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
by Zacks Equity Research
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
Does Galapagos NV (GLPG) Have the Potential to Rally 34% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.4% in Galapagos NV (GLPG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Down 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
by Zacks Equity Research
Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Strength Seen in Galapagos NV (GLPG): Can Its 8% Jump Turn into More Strength?
by Zacks Equity Research
Galapagos NV (GLPG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Are Medical Stocks Lagging Galapagos (GLPG) This Year?
by Zacks Equity Research
Here is how Galapagos NV (GLPG) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA
by Zacks Equity Research
The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.
Wall Street Analysts See a 28% Upside in Galapagos NV (GLPG): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 28.3% upside potential for Galapagos NV (GLPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Galapagos (GLPG) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Galapagos NV (GLPG) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs
by Zacks Equity Research
Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Costs headwinds offset volume and price growth.
Has Galapagos (GLPG) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Galapagos NV (GLPG) and MedAvail Holdings, Inc. (MDVL) have performed compared to their sector so far this year.
Strength Seen in Galapagos NV (GLPG): Can Its 5% Jump Turn into More Strength?
by Zacks Equity Research
Galapagos NV (GLPG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study
by Zacks Equity Research
Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.
Galapagos (GLPG) Falls on Inflammatory Study Data Readout
by Zacks Equity Research
Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.
Gilead (GILD) & Galapagos Discontinue Development of IPF Drug
by Zacks Equity Research
Gilead (GILD) and partner Galapagos announce their decision to discontinue development of ziritaxestat in patients with idiopathic pulmonary fibrosis.
Gilead (GILD) Tops Q4 Earnings & Sales on Strong Veklury Demand
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the fourth quarter owing to increased Veklury sales as the coronavirus pandemic continues.
Will Strong Veklury Sales Aid Gilead's (GILD) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports fourth-quarter 2020 results.
Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand
by Zacks Equity Research
Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.
Company News for Dec 17, 2020
by Zacks Equity Research
Companies In The News Are: GOOGL, LUV, TLRY, APHA, GLPG, GILD.
Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal
by Zacks Equity Research
Gilead (GILD) decides to not pursue FDA approval of filgotinib for the treatment of RA.